Does Anti Platelet Agents Interact with Osimertinib?
Anti Platelet Agents and Osimertinib have a moderate drug interaction according to U.S. FDA drug labeling data. Osimertinib increases substrate exposure, potentially increasing toxicity risk. Monitor for adverse reactions of the substrate. The mechanism involves osimertinib inhibition of bcrp or p-gp increases substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Osimertinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Anti Platelet Agents and Osimertinib occurs because osimertinib inhibition of bcrp or p-gp increases substrate exposure. Clinically, this means osimertinib increases substrate exposure, potentially increasing toxicity risk. monitor for adverse reactions of the substrate. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Anti Platelet Agents and your doctor is considering prescribing Osimertinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider